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Abstract 
Purpose: Aging is a poor prognostic factor for melanoma. We have shown that 
melanoma cells in an aged microenvironment, are more resistant to targeted therapy 
than identical cells in a young microenvironment. This is dependent on age-related 
secreted factors. Klotho is an age-related protein, whose serum levels decrease 
dramatically by age 40. Most studies on klotho in cancer have focused on the expression 
of klotho in the tumor cell. We have shown that exogenous klotho inhibits internalization 
and signaling of Wnt5A, which drives melanoma metastasis and resistance to targeted 
therapy. We investigate here whether increasing klotho in the aged microenvironment 
could be an effective strategy for the treatment of melanoma.  
Experimental Design. PPARγ increases klotho levels, and is increased by glitazones. 
Using rosiglitazone, we queried the effects of rosiglitazone on Klotho/ Wnt5A crosstalk, 
in vitro and in vivo, and the implications of that for targeted therapy in young vs. aged 
animals.  
Results: We show that rosiglitazone increases klotho and decreases Wnt5A in tumor 
cells, reducing the burden of both BRAF-inhibitor sensitive, and BRAF inhibitor-resistant 
tumors in aged, but not young mice. However, when used in combination with PLX4720, 
tumor burden was reduced in both young and aged mice, even in resistant tumors. 
Conclusions: Using glitazones as adjuvant therapy for melanoma may provide a new 
treatment strategy for older melanoma patients who have developed resistance to 
vemurafenib. As klotho has been shown to play a role in other cancers too, our results 
may have wide relevance for multiple tumor types. 
 
 
Translational Relevance  
Increasing klotho via PPARγ activation using rosiglitazone may provide new and 
effective strategies for the treatment of therapy-resistant melanoma in older patients. 
Our data indicate that, contrary to the majority of conventional therapies, alternate 
approaches that target age-associated molecules may be selectively effective in aged 
patients. 
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Introduction  
   Dermal fibroblasts undergo age-related changes that result in altered secretory 
profiles. We have recently shown that these age-related changes can drive melanoma 
progression, and therapy resistance. We found that one of the ways in which the aged 
microenvironment promoted metastasis was via secretion of an inhibitor of canonical 
Wnt signaling, sFRP2. sFRP2 secreted by aged dermal fibroblasts suppressed β-catenin 
signaling in melanoma cells. The loss of β-catenin signaling has been associated with a 
increase in metastatic capacity of melanoma cells, as well as a decrease in sensitivity to 
vemurafenib. We found this to be true for melanoma cells in an aged microenvironment 
as well, such that the restoration of β-catenin signaling by anti-sFRP2 antibody in vivo 
re-sensitized tumors to vemurafenib, and decreased their metastatic ability.  In 
melanoma, the secreted non-canonical Wnt signaling molecule, Wnt5A, also drives the 
metastatic progression of melanoma (1) and resistance to targeted therapy, in part by 
inhibiting β-catenin signaling (2). Wnt5A is therefore significantly associated with poorer 
prognosis in melanoma. We have recently asked what factors might regulate Wnt5A, 
and we, and others, have identified the anti-aging hormone klotho as a regulator of Wnt 
signaling (3, 4).  
Klotho is a circulating serum factor, which is lost during aging. Overexpression of 
klotho in transgenic mice promotes longevity (5). Conversely, the knockout of klotho 
results in a complex premature aging phenotype, where mice that are born 
phenotypically normal develop atherosclerosis, osteoporosis, skin atrophy and bone 
degeneration.  Klotho has also been shown to decrease Wnt signaling (3). We 
discovered that Wnt5A is bound to the surface of melanoma cells by heparan sulfate 
proteogylcans (6), and klotho, which has sialidase activity (7), cleaves Wnt5A from the 
proteoglycans, such that it cannot be internalized and signal (4). Once this occurs, 
Wnt5A mRNA expression also decreases, as Wnt5A increases PKC, which in turn 
signals to stabilize Wnt5A mRNA. Klotho therefore affects both Wnt5A internalization 
and mRNA expression, and treatment of Wnt5A-high cells with recombinant klotho 
significantly inhibits their invasion (4). 
In addition to its sialidase activities, klotho plays essential roles in maintaining 
phosphate homeostasis, inhibiting oxidative stress, suppressing cellular senescence and 
modulating insulin receptor signaling (8-11). The loss of klotho is thought to correspond 
either directly or indirectly to increased insulin resistance, which is associated with 
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diabetes (5). Recently, there has been much interest in using anti-diabetic drugs to treat 
melanoma. Drugs such as metformin and phenformin have been suggested because 
they affect mitochondrial biogenesis and changes in mitochondrial biogenesis affect 
melanoma cell response to vemurafenib, and contribute to drug resistance (12, 13).  
Another class of drugs used to treat diabetes is the glitazones, which are 
agonists of the peroxisome proliferator-activated receptor, PPARγ, a nuclear hormone 
receptor that controls the transcription of multiple genes involved in lipid biogenesis and 
metabolism (14). Klotho is a transcriptional target of PPARγ, such that PPARγ increases 
klotho mRNA (15).  Wnt5A has recently been shown to inhibit expression of PPARγ via 
the activation of CAMKII (16). We previously reported that Wnt5A also inhibited klotho, 
largely at the mRNA level, but at the time did not have a mechanism by which it did so. 
We hypothesized that Wnt5A may be able to repress klotho expression via CAMKII- 
mediated suppression of PPARγ. Here we test and confirm this hypothesis. We further 
show that using available PPARγ agonists, such as rosiglitazone (trade name Avandia), 
can increase serum levels of klotho in the blood and in the tumor microenvironment, and 
decrease Wnt5A. Intriguingly we also find that rosiglitazone decreases the growth of 
BRAF resistant melanomas in aged, but not young mice.  
 
Methods 
CELL CULTURE 
WM858, WM793, WM164 and 1205LU cells were maintained in MCDB153 (Sigma, St 
Louis, MO)/ L-15 (Cellgro, Manassas, VA) (4:1 ratio) supplemented with 2% FBS and 
1.6 mM CaCl2 (Tumor growth media). WM983B cells were maintained in DMEM 
(Invitrogen, Carlsbad, CA), supplemented with 5% FBS, 100 units/ml penicillin and 
streptomycin and 4 mM L-glutamine. The PLX4720 resistant cell lines were cultured in 
media same as the parent lines in presence of PLX4720 (Chemietek). FS5, FS4, cells 
were maintained in RPMI (Invitrogen, Carlsbad, CA), supplemented with 10% FBS, 100 
units/ml penicillin and streptomycin and 4 mM L-glutamine. Yumm1.7 melanoma cells 
derived from the BRAFV600E/PTEN-/-/CDKN2A-/- mouse model of melanoma and 
human fibroblasts were maintained in DMEM, supplemented with 10% FBS, 100 units/ml 
penicillin and streptomycin and 4 mM L-glutamine.  Yumm1.7 cells were cultured to 
resistance in 10M PLX4720. Keratinocytes were maintained in keratinocyte SFM 
supplemented with human recombinant Epidermal Growth Factor 1-53 (EGF 1-53) and 
Bovine Pituitary Extract (BPE) (Invitrogen). All the cell lines were cultured at 37°C in 5% 
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CO2. Cell stocks were fingerprinted using AmpFLSTR® Identifiler® PCR Amplification 
Kit from Life Technologies TM at The Wistar Institute Genomics Facility. Although it is 
desirable to compare the profile to the tissue or patient of origin, our cell lines were 
established over the course of 40 years, long before acquisition of normal control DNA 
was routinely performed. However, each STR profile is compared to our internal 
database of over 200 melanoma cell lines, as well as control lines, such as HeLa and 
293T. STR profiles are available upon request. Cell culture supernatants were 
mycoplasma tested using a Lonza MycoAlert assay at the University of Pennsylvania 
Cell Center Services.  
 
TREATMENTS 
Cells were treated with 100 ng/ml of recombinant Wnt5A (R&D Systems, cat. no. 
645WN010CF) for 16 h or 10ng/ml of recombinant klotho (R&D Systems, cat. no. 5334-
KL-025 ) for 48 h. KN93 (Cayman, cat. no. 13319) was used at a final concentration of 
10M and Rosiglitazone (Sigma-Aldrich, cat. no. NBP1-51462) at 10M for 48 h unless 
otherwise stated. BRAF resistance subclones were seeded overnight in the absence of 
plx4720 and then treated as indicated. 
 
WESTERN BLOTTING 
Western blotting was done as described in (17). Briefly, total protein lysate of 50-65g 
was run on 4-12% NuPAGE Bis Tris gel (Invitrogen, cat no. NW 041222BOX), 
transferred onto PVDF membrane using iBlot 2, Life technologies and blocked in 
5%milk/TBST. To analyze level of secretory klotho, conditioned media from fibroblasts 
was run on 4-12% NuPAGE Tris gel and total protein lysate from the fibroblasts was 
used to probe for HSP90 as loading control. Primary antibodies were used at the 
following concentrations: biotinylated Wnt5A (500 ng/ml; R&D Systems, cat. no. 
BAF645), Klotho (1:500; abcam, cat. no. ab98111), HSP90 (1:4000; Cell Signaling, cat. 
no. BAF645), CAMKII (1:500; Cell Signaling, cat. no. BAF645), CAMKII alpha/delta (p 
Thr286) (1:500; NBP1-51462, Novus), pERK (1:500; Cell Signaling, cat no. 4370S), ERK 
(1:500; Cell Signaling, cat no. 4696S). All primary antibodies were diluted in 5% 
milk/TBST and incubated overnight at 4°C. The membranes were washed in TBST and 
probed with the corresponding HRP-conjugated secondary antibody (0.2–0.02 μg/ml of 
anti-mouse, streptavidin, or anti-rabbit). Proteins were visualized using ECL prime 
(Amersham, Uppsala, Sweden) or Luminata Crescendo (Millipore, Billerica, MA, USA). 
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ORGANOTYPIC 3D SKIN RECONSTRUCTS 
Organotypic 3D skin reconstructs were generated as previously described (18). Briefly, 
6.4 x 104 fibroblasts were plated in each insert on top of the acellular layer (BD, cat. no. 
355467 and Falcon, cat. No. 353092) and incubated for 45 min at 37°C in a 5% CO2 
tissue culture incubator. The tissue culture trays were filled with DMEM containing 10% 
FBS and incubated for 4 days. Reconstructs were then incubated for 1 h at 37°C in 
HBSS containing 1% dialyzed FBS (wash media). Washing media was removed and 
replaced with reconstruct media. Keratinocytes (4.17 x 105) and melanoma cells (8.3 x 
104) were added to the inside of each insert.  Media was changed every other day until 
day 18, reconstructs were then harvested, fixed in 10% formalin, paraffin embedded, 
sectioned and stained.  
 
IMMUNOHISTOCHEMISTRY (IHC) 
Immunohistochemistry was performed on paraffin embedded sections as described 
previously (18). Briefly, Paraffin embedded sections were rehydrated through a xylene 
and alcohol series rinsed in H2O and washed in PBS. Antigen retrieval was performed 
by steaming for 20 min in target retrieval buffer (Vector Labs, Burlingame, CA) and 
steamed for 20 min. Samples were blocked in a peroxidase blocking buffer (Thermo 
Scientific) followed by Protein block (Thermo Scientific) and incubated in appropriate 
primary antibody diluted in antibody diluent (S0809, Dako) at 4°C overnight in a 
humidified chamber. Samples were then incubated in biotinylated anti-rabbit or 
polyvalent secondary antibody (Thermo Scientific) followed by streptavidin-HRP solution. 
Samples were then washed in PBS and incubated in 3-Amino-9-Ethyl-l-Carboazole 
(AEC) chromogen. Finally, samples were washed in H2O, incubated in Meyer’s 
hematoxylin for 1 min, rinsed in cold H2O, and mounted in Aquamount. Patient samples 
were collected under IRB exemption approval for protocol #EX21205258-1.   
 
IMMUNOFLUORESCENCE (IF) 
Cells were seeded onto glass cover slips and incubated overnight. These cells were 
then treated with fibroblast conditioned media, KN93 or Rosiglitazone with the indicated 
dose for     48 h. Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% 
TritonX-100, blocked with 1% BSA and stained for primary antibodies as previously 
described (18). When staining for klotho cells were not permeabilized. For 
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immunofluorescence staining in the 3D skin reconstructs, the paraffin embedded 
sections were rehydrated, processed for antigen retrival and blocked as described for 
IHC. Primary antibodies were used at the following concentrations: Klotho (1:150), 
PPAR (1:100, abcam, cat. No. ab19481), Wnt5A (1:50), HMB45 (1:50, abcam, cat. No. 
ab787) and incubated at 4°C overnight. Cells were washed in PBS and incubated with 
the appropriate secondary antibody (1:2000, Invitrogen) for 1 h at room temperature and 
mounted in Prolong Gold anti-fade reagent containing DAPI (Invitrogen). Images were 
captured on a Leica TCS SP5 II scanning laser confocal system. 
 
LENTIVIRAL INFECTION 
shRNA against human klotho was obtained from Sigma-Aldrich, KL MISSION shRNA 
Bacterial Glycerol Stock. Klotho shRNA clones used were: TRCN0000158823 and 
TRCN0000160036. Lentiviral production was performed as described previously (18). 
Briefly, 293T cells were co-transfected with Klotho shRNA vector and lentiviral 
packaging plasmids (pCMV-dR8.74psPAX2, pMD2.G). The supernatant containing virus 
was harvested at 36 and 60 hours, combined and filtered through a 0.45µm filter and 
stored in -80 degrees till further use. For transduction, the cells were layered overnight 
with lentivirus containing 8 µg/ml polybrene. The cells were allowed to recover for 24 
hours and then selected using 1µg/ml puromycin. 
 
siRNA TRANSFECTION 
KL siRNA  and negative control siRNA (100nM,  ambion) were transfected into cells 
using Lipofectamine 2000 (Thermo Fisher Scientific) as per manufacturer’s protocol. 
 
MITOCHONDRIAL STAINING 
Melanoma cells treated with indicated conditions were seeded onto a 384 well plate at 
3000 cells/well in triplicate (PerkinElmer cell carrier). For analyzing mitochondrial mass, 
cells were incubated with MitoTracker® Green FM (M7514, ThermoFisher Scientific) at 
1M concentration for 1 h. To analyze production of superoxide by mitochondria, cells 
were incubated with MitoSOX™ Red reagent (M36008, ThermoFisher Scientific) at a 
final concentration of 5M for 10 min, washed extensively and were imaged using 
PerkinElmer Operetta. The fluorescent signal was quantified using Harmony 3.0 
software. Readings were normalized to cell number which was determined by Hoescht 
staining (Hoechst 33342, Invitrogen). Cells seeded on coverslips were also stained with 
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MitoTracker® Red CM-H2Xros (M7513, Thermofisher Scientific) at 1M concentration 
for 1 h, fixed with formaldehyde 4% and mounted in Prolong Gold anti-fade reagent. 
Images were captured on a Leica TCS SP5 II scanning laser confocal system. 
Fluorescence were normalized to cell number. 
 
TCGA DATABASE ANALYSIS 
The RNAseq and Clinical data set for skin cutaneous melanoma (19) was downloaded 
from TCGA (http://cancergenome.nih.gov/). Patient ages were group into 10 year age 
ranges. Patient sample information is included in Supplementary Table 1.  
 
REAL TIME PCR 
RNA was extracted using Trizol (Invitrogen) and RNeasy Mini kit (Qiagen) as previously 
described (18). cDNA was prepared using iscript DNA synthesis kit (Bio-Rad, cat. No. 
1708891). Gene expression was quantified using SYBR green method of qPCR and 
mRNA levels were compared to standard curves. qPCR was performed on an ABI 
StepOnePlus sequence detection system using fast conditions and samples were 
normalized against the 18S gene, using Universal 18S primers ( Invitrogen, cat. No. 
AM1718). Expression was calculated using the standard curve method according to the 
manufacturer’s protocol (Perkin Elmer, Waltham, MA). The sequences for primers are  
Klotho forward primer: GCTCTCAAAGCCCACATACTG; Klotho reverse primer: 
GCAGCATAACGATAGAGGCC Wnt5a forward primer: AGGGCTCCTACGAGAGTGCT; 
Wnt5a reverse primer: GACACCCCATGGCACTTG.  
 
CELL VIABILITY ASSAY (MTS)  
Cell viability was determined using CellTiter 96 Aqueous One Solution Cell Proliferation 
Assay according to manufacturers protocol. Briefly, cells were seeded in flat bottom 96-
well plates and allowed to adhere overnight. The next day, cells were treated with the 
indicated drugs for indicated time period. Following treatments, cells were incubated with 
MTS dye (20 μl/well) for 2 h. Absorbance was determined at 490nm using an EL800 
microplate reader (BioTek, Winooski, VT). The percent cell viability was calculated by 
converting the experimental absorbance to percentage of control and plotted vs drug 
concentration. The values were then analyzed using a nonlinear dose-response analysis 
in GraphPad Prism. 
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IN VIVO TUMOR BURDEN ASSAY 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC) (IACUC #112503X_0) and were performed in an Association for the 
Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited facility. 
YUMM1.7 parental or YUMM1.7_BR (2.5 x 105 cells) were injected subcutaneously into 
young (6 week old) and aged (52 week old) C57/BL6 mice (Charles River). Tumor sizes 
were measured every 3-4 days using digital calipers, and tumor volumes were 
calculated using the following formula: volume = 0.5 x (length x width2). When resulting 
tumors reached 200 mm3, mice were fed with either AIN-76A chow or AIN-76A chow 
containing 417 mg/kg PLX4720. Time-to-Event (survival) was determined by a 5-fold 
increase in baseline volume (~1000 mm3) and was limited by the development of skin 
necrosis. For treatment with recombinant mouse Klotho (R&D systems, Cat. No. 
645WN010CF) or Rosiglitazone, mice were injected intraperitoneally with recombinant 
Klotho, 0.02mg/Kg every 2 days or with Rosiglitazone, 10mg/Kg every other day. To 
analyze klotho levels in serum, serum was isolated from blood collected by sub-
mandibular bleeding and Klotho levels were analyzed by western blotting. At the end of 
experiment mice were euthanized, tumors were harvested and a portion of the tumors 
were embedded in paraffin and sectioned. 
 
STATISTICAL ANALYSIS 
For in vitro studies, a Student's t-test or Wilcoxon rank-sum test (Mann Whitney) was 
performed for two-group comparison. Estimate of variance was performed and 
parameters for the t-test were adjusted accordingly using Welch’s correction. ANOVA or 
Kruskal-Wallis test with post-hoc Bonferroni's or Holm-Sidak’s adjusted p-values was 
used for multiple comparisons. For in vivo studies, repeated measures analysis of 
variance (Anova) was calculated between samples. Holm Sidak correction was 
performed. For other experiments, Graphpad/Prism6 was used for plotting graphs and 
statistical analysis. Data was represented as +/- SEM. Significance was designated as 
follows: *, p<0.05; **, p<0.01; ***, p<0.001. 
 
Results 
Manipulation of klotho in dermal fibroblasts affects Wnt5A expression in 
melanoma cells 
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Klotho expression is decreased in aged human skin (Figure 1a). We have recently 
shown that aged dermal fibroblasts can drive the metastasis and therapeutic resistance 
of melanoma largely through secreted factors. To investigate if the loss of klotho from 
fibroblasts contributes to the increased aggression and therapy resistant phenotype of 
melanoma cells in the aged microenvironment, we assayed dermal fibroblasts derived 
from non-melanoma, healthy donors who were either young (25-35 years old) or aged 
(55-65 years old) for expression of klotho. All fibroblast experiments were normalized to 
cell number. As expected, aged dermal fibroblasts demonstrated a decrease in klotho 
expression as compared to young fibroblasts, as measured by RT-PCR, Western 
analysis, (Figure 1b,c), and immunofluorescent analysis (Supplementary Figure 1a). 
Further, klotho expression was also decreased in the serum of aged mice, as measured 
by ELISA (Supplementary Figure 1b). In skin reconstructs built with aged and young 
fibroblasts, young fibroblasts continued to express klotho, whereas aged fibroblasts did 
not (Supplementary Figure 1c). Melanoma cells, surprisingly, recapitulated the age-
related klotho expression of fibroblasts: if young fibroblasts were present in the skin 
reconstruct, melanoma cells in the proximity also expressed klotho. If aged fibroblasts 
were present, melanoma cells expressed lower levels of klotho (Figure 1d). TCGA 
analysis of melanoma samples revealed that klotho is indeed decreased in melanoma 
patients as they age. The difference is most significant under 40 (the age where klotho is 
lost in the serum) and over 55 (where the incidence of melanoma increases rapidly), 
however expression decreases steadily by decade (Supplementary Figure 1d, patient 
information provided in Supplementary Table 1).  
Since we have previously shown that exogenous klotho affects Wnt5A 
internalization and expression, we asked whether differences in the amount of klotho 
secreted from young vs. aged fibroblasts affected Wnt5A accordingly in melanoma cells. 
To confirm that any effects observed were fibroblast-related, we treated melanoma cells 
with media from young and aged fibroblasts, as well as with un-conditioned media with 
and without 10% fetal bovine serum (FBS). As expected, in the melanoma cells treated 
with serum-free media, Wnt5A was elevated (Figure 1e). Consistent with our hypothesis, 
Wnt5A expression was low in melanoma cells treated with both serum-containing media 
and media from young fibroblasts. However, when we tested the serum-containing 
media for klotho we found that it contained klotho (data not shown).  In contrast, aged 
fibroblast media resulted in an elevated level of Wnt5A expression (Figure 1e, 
Supplementary Figure 1e). Melanoma cells in aged fibroblast conditioned media also 
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have less klotho mRNA as compared to the cells in young fibroblast conditioned media 
(Supplementary Figure 1 f).  
We next observed Wnt5A regulation by the aged microenvironment in artificial 
skin reconstructs made with young or aged fibroblasts, into which we put identical 
melanoma cell lines. As noted above (Figure 1d) melanoma cells recapitulate the klotho 
expression of the fibroblasts, such that melanoma cells in reconstructs made with young 
fibroblasts express klotho, and melanoma cells in reconstructs made with aged 
fibroblasts express less klotho. Consistent with our hypothesis that klotho modulates 
Wnt5A expression, in skin reconstructs made with aged fibroblasts and melanoma cells, 
Wnt5A was increased in melanoma cells, compared to identical skin reconstructs built 
with young fibroblasts (Figure 1f, additional cell line, Supplementary Figure 1i, j). To 
determine whether this differential Wnt5A expression could be altered by manipulating 
klotho in young and aged fibroblasts, we knocked down klotho using sh_RNA against 
klotho (sh_klotho) in young fibroblasts (Supplementary Figure 1g, h) and observed an 
increase in Wnt5A in melanoma cells exposed to sh_klotho fibroblast media. 
Conversely, treating aged fibroblasts with recombinant klotho (rklotho) decreased Wnt5A 
in melanoma cells exposed to rklotho-supplemented aged media (Figure 1g). We 
confirmed this result in skin reconstructs built using young fibroblasts treated with either 
a control (scrambled) shRNA, or with a klotho shRNA. In the reconstructs built with the 
klotho knockdown fibroblasts, the levels of klotho in the melanoma cells decrease 
(Figure 1h) and the level of Wnt5A increases (Figure 1i), mimicking the aged fibroblast 
conditions. Together these data indicate that the loss of klotho in the aged 
microenvironment, specifically in dermal fibroblasts, increases Wnt5A in melanoma cells. 
We have shown extensively that Wnt5A is involved in multiple aspects of tumor 
progression. Therefore, reconstitution of Wnt5A upon klotho loss during aging may be 
another mechanism leading to the increased aggression of melanoma in the elderly.  
 
Wnt5A suppresses klotho via CAMKII mediated inhibition of PPARγ.  
We previously showed that Klotho acts as a sialidase, cleaving Wnt5A away from 
the surface of melanoma cells. We next wanted to determine the mechanism by which 
Wnt5A can regulate klotho. Klotho is a target of PPARγ, a regulator of fatty acid storage 
and glucose metabolism (15). PPARγ is phosphorylated and degraded by the activation 
(phosphorylation) of CAMKII, which in turn is a direct target of Wnt5A (16). Thus, we 
hypothesized that Wnt5A regulates klotho expression via CAMKII mediated degradation 
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of PPARγ (outlined in Figure 2a). Indeed, treatment of melanoma cells with rWnt5A 
increased CAMKII phosphorylation (Figure 2b) and decreased PPARγ and klotho (Figure 
2c). Conversely, when aged fibroblasts were treated with the CAMKII inhibitor KN93, 
mRNA expression of klotho was increased (Figure 2d), as was protein expression of 
PPARγ (Figure 2e). Even at the highest doses, KN93 was not toxic to fibroblasts 
(Supplementary Figure 2a, b). To determine whether KN93 had similar effects on 
melanoma cells, we treated melanoma cells with KN93 (10μM, 48h) and demonstrated 
that PPARγ and klotho were restored (Figure 2f, g). Consistently, exploration of PPARγ 
expression levels in the TCGA database revealed that, like klotho, PPARγ levels were 
decreased in older melanoma patients (Supplementary Figure 2c, aged vs. young at 
different decades of life).  
As our data above suggested that activation of PPARγ should increase klotho, 
and regulate Wnt5A, we treated aged fibroblasts with the PPARγ agonist rosiglitazone, 
which increased PPARγ, and klotho (Figure 2h, i). Melanoma cells treated with 
rosiglitazone demonstrated a decrease in the secreted form of Wnt5A in the lysate 
(Supplementary Figure 2d, upper band). As in fibroblasts, we observed increases in both 
PPARγ and klotho in melanoma cells treated with rosiglitazone (Supplementary Figure 
2e). Like KN93, Rosiglitazone was not toxic to either fibroblasts or melanoma cells at 
high doses (Supplementary Figure 2f, g). To translate these findings in vivo, we used 
Yumm1.7 melanoma cells derived from the BRAFV600E/PTEN-/-/CDKN2A-/- mouse model 
of melanoma, and injected them into C57BL/6 mice. When tumors were palpable, we 
treated one set of aged mice with 10mg/kg of rosiglitazone and one set with 0.02mg/kg 
of recombinant klotho, and treated a third set with PBS/DMSO vehicle control.   Tumor 
burden was significantly reduced as compared to control by treatment with either 
rosiglitazone or recombinant klotho (Figure 2j). Treatment of aged mice with 
rosiglitazone or recombinant klotho decreased Wnt5A and increased klotho levels in the 
tumor (Figure 2k). Together these data suggest that using rosiglitazone as an agent to 
increase PPARγ and klotho can decrease Wnt5A and inhibit tumor growth in an aged 
microenvironment.  
 
Rosiglitazone-mediated inhibition of Wnt5A can inhibit growth of BRAF-inhibitor 
resistant cells.   
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One of the first line therapies for melanoma is the drug vemurafenib, which 
targets a mutant BRAF protein (BRAFV600E). Our previous work demonstrated that 
Wnt5A can promote resistance to targeted therapy in melanoma (2, 17), and we support 
this by showing that knockdown of Wnt5A can increase the sensitivity of melanoma cells 
to PLX4720, the tool compound for Vemurafenib (Supplementary Figure 3a, b). Further, 
Wnt5A is more highly secreted by aged as compared to young fibroblasts 
(Supplementary Figure 3c), which is in keeping with our previous data showing that 
melanomas in an aged microenvironment are more resistant to vemurafenib, largely due 
to changes in Wnt signaling (18). Importantly, it has been shown that Wnt5A can signal 
to activate ERK, and CAMKII, also a target of Wnt5A, activates the Raf signaling 
pathway further. This represents a way to maintain activation of the MAPK pathway, 
regardless of mutational status. To determine if manipulating this pathway in melanoma 
cells could affect resistance of melanoma cells to BRAF inhibition, we created a resistant 
subclone of Yumm1.7 cells that we could use in vivo. These subclones are as resistant 
in vitro to PLX4720 (the tool compound for vemurafenib) as are WM983B BRAF 
inhibitor-resistant subclones (Supplementary Figure 4a). Next we analyzed the 
Yumm1.7, WM983B, WM793 and their resistant subclones for Wnt5A and PO4-ERK. 
Each of these cell lines bears a different set of mutations (Supplementary Table 2). In 
each case, both Wnt5A and PO4-Erk were elevated (Figure 3a). This was also 
concomitant with the loss of klotho and PPARg expression (Supplementary Figure 4b-f). 
We then asked whether increasing klotho via rosiglitazone reduced PO4-Erk signaling, 
via downregulation of Wnt5A. PO4-Erk is decreased in BRAF-resistant cell lines after 
treatment with rosiglitazone (Figure 3b) and this is concomitant with the decrease in 
Wnt5A (Supplementary Figure 4g). KN93 is similarly able to cause decreases in both 
PO4-Erk and Wnt5A (Supplementary Figure 4h). We then asked whether 
transcriptionally silencing klotho would prevent rosiglitazone from decreasing ERK 
activity and decreasing Wnt5A. Knocking down klotho in young fibroblasts increased 
PO4-Erk and Wnt5A (Supplementary Figure 4i). In melanoma cells treated with 
rosiglitazone, there is a reduction of both Wnt5A and PO4-ERK. However, first knocking 
down klotho results in activated Erk, and sustained Wnt5A signaling, even in the 
presence of rosiglitazone (Figure 3c, Supplementary Figure 4j). These data suggest that 
Rosiglitazone is mediating its effects on the Erk pathway via klotho-mediated 
suppression of Wnt5A.  
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We have previously shown that tumors in an aged microenvironment are more 
resistant to targeted therapy. Therefore, we examined whether increasing klotho in the 
microenvironment could affect response to PLX4720. We took aged fibroblasts, and 
treated them with rosiglitazone. We then exposed BRAF resistant melanoma cells to the 
media from the treated fibroblasts, in the presence or absence of PLX4720. Western 
analysis of PO4-ERK (Figure 3d) demonstrates that rosiglitazone treatment of the 
fibroblasts also reduces PO4-ERK levels in melanoma cells. We have shown that 
mitochondrial ROS marks response to PLX4720, such that increases in mito-Sox 
correlate to increased resistance (Supplementary Figure 5a,b). As with PO4-ERK, mito-
sox activity is lowered by rosiglitazone in melanoma cells incubated with aged 
fibroblasts, both in the presence and absence of PLX4720 (Figure 3e, Supplementary 
Figure 5c-e).  
Taken together these data suggested that targeting klotho in both the melanoma 
cells and the microenvironment in aged mice should have effects on BRAFi resistant 
melanomas. To test this hypothesis in vivo, we treated Yumm1.7BR resistant cells with 
rosiglitazone or klotho, in the presence and absence of PLX4720 and demonstrated that 
these treatments decreased Wnt5A (Supplementary Figure 5f). Yumm1.7BR cells were 
injected subcutaneously into aged mice. Treatment with PLX4720 alone did not affect 
tumor growth compared to controls, whereas treatment with rosiglitazone alone, and the 
combination of rosiglitazone and PLX4720, impeded the rate of tumor growth (Figure 3f). 
The combination was not more effective than rosiglitazone alone. To determine if these 
results differed in young mice, we repeated the identical experiments in 8-week old mice. 
In young mice, Yumm1.7BR cells re-acquired sensitivity to PLX4720, in keeping with 
previous data from our lab that indicated that melanoma cells are more sensitive to 
BRAFi in a young microenvironment (18). Intriguingly, treating young mice with 
rosiglitazone alone accelerated tumor growth; however, rosiglitazone + PLX4720 
decreased tumor burden compared to PLX4720 alone (Figure 3g). To assay whether 
klotho was differentially increased in Yumm1.7BR cells in rosiglitazone-treated aged vs. 
young mice, we examined the serum of mice for klotho expression, and stained the 
tumors for klotho.  In aged mice, klotho expression is low in Yumm 1.7BR tumors and in 
serum, and klotho increases in aged mice upon treatment with rosiglitazone (Figure 3h, 
left). In young mice however, klotho is high at baseline in both the tumor and mouse 
serum, and elevated even further by rosiglitazone treatment (Figure 3h, right). These 
data indicate that rosiglitazone may be a unique therapy for older patients, and while it 
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cannot re-sensitize melanoma cells to vemurafenib, it can still reduce tumor burden, both 
in BRAF-inhibitor sensitive and resistant cells in aged animals. Rosiglitazone may be a 
viable alternate strategy to reduce tumor burden in older patients who have developed 
resistance to BRAF inhibitors. Our data suggest also that since PO4-Erk is reduced by 
direct treatment of melanoma cells with rosiglitazone, the right dosing schedule of 
rosiglitazone and PLX4720 may provide additional benefit in combination with BRAF 
inhibitors in young patients as well, which will be the subject of further study in our 
laboratory.  
 
Discussion 
The role of klotho in aging has been well documented. The loss of klotho has 
also been implicated in the progression of multiple tumor types, including lung (20), 
cervical (21) and gastric cancer (22). In addition, we have shown that treating melanoma 
cells with recombinant klotho can reduce their invasion by inhibiting Wnt5A signaling, 
which is elevated in metastatic melanoma cells. We have also shown that, in addition to 
promoting metastasis, Wnt5A can increase resistance to vemurafenib. Maintaining 
klotho in aged patients then, could have the twin benefits of decreasing metastasis and 
inhibiting therapy resistance. Since klotho is lost during aging, and we have recently 
shown that aging promotes melanoma metastasis and therapy resistance (18), here we 
asked whether klotho loss in the aged microenvironment, specifically in fibroblasts, 
promotes Wnt5A expression and affects therapy resistance. In this study we confirm that 
klotho is decreased in the aged skin microenvironment, and manipulation of klotho in 
aged and young dermal fibroblasts affects Wnt5A expression in melanoma cells. We 
also show, for the first time, that Wnt5A can regulate klotho and that it does so by 
CAMKII-mediated suppression of PPARγ. When Wnt5A is absent, PPARγ activation 
increases transcription of klotho.  
Because some anti-diabetic drugs (e.g. metformin) have activity against 
melanoma (23), and because some of these medications are PPARγ agonists, there has 
been much interest in the use of PPARγ agonists to treat cancer. However, the studies 
performed so far provide conflicting data as to whether PPARγ agonists are beneficial. In 
colon cancer, studies indicate that malignancy can be reversed by rosiglitazone, 
pioglitazone and other thiazolidinediones (TZD) (24-26), but Phase II clinical trials do not 
support this (27). Similarly, in breast cancer, late-stage tumors are not affected by TZD. 
However, a more recent study has shown that if the glitazone is administered earlier, to 
Research. 
on March 9, 2017. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 23, 2017; DOI: 10.1158/1078-0432.CCR-17-0201 
 16
less aggressive tumors, i.e., HER2+ breast cancer, then it does have protective effects 
(28). In the current study, we identify yet another parameter that may affect response to 
glitazones, and that is age. We show that rosiglitazone can increase levels of klotho in 
the serum of aged mice bearing melanoma, and that this translates to an inhibition of 
tumor growth similar to treating mice directly with klotho. Treating BRAF inhibitor 
resistant cells with rosiglitazone reduces ROS in the mitochondria, and kills tumor cells. 
While we cannot claim that rosiglitazone re-sensitizes cells to vemurafenib, because at 
the doses used there was no added benefit to rosiglitazone + PLX4720 vs. rosiglitazone 
alone, it is quite clear that rosiglitazone may prove to be effective against BRAFi 
resistant melanoma, when other options have failed. Similarly, increasing klotho with 
rosiglitazone inhibits the growth of both BRAFi-sensitive and BRAFi-resistant melanoma 
equally effectively in aged animals.  
Increasing rosiglitazone increased klotho levels, decreased Wnt5A and 
decreased tumor burden in aged mice. However, this was not the case in young mice, 
and we were fascinated to find that treatment with rosiglitazone differed in young vs. 
aged mice. First, we have recently shown that changes in the aged microenvironment 
(e.g., increases in ROS and sFRP2) can drive increased resistance to targeted therapy 
(18). In that study, placing PLX4720-sensitive tumors in aged mice increased their ability 
to resist therapy. Here we show that the opposite is also true, i.e., that placing resistant 
tumors in young mice, slightly, but significantly, increases their sensitivity to PLX4720. 
Further, the combination of PLX4720 and rosiglitazone is effective in young mice, and 
unlike in aged mice, rosiglitazone appears to sensitize tumors to PLX4720. We have 
shown in this study that treatment of melanoma with rosiglitazone lowers PO4-Erk levels, 
which may be enough in the young microenvironment to further sensitize melanomas to 
PLX4720. However, rosiglitazone alone is ineffective in treating resistant tumors in 
young animals, and actually increases tumor burden in young mice. The mechanism for 
this is not entirely clear, but may be due to a klotho threshold present in cells, which 
determines their susceptibility to PLX4720 and other MAPK targeting agents. In this 
case, endogenous levels of klotho in young mice may partially re-sensitize resistant 
tumors to targeted therapy, and increasing klotho with rosiglitazone in aged animals 
where klotho is endogenously low can decrease the growth of resistant tumors. 
However, raising klotho further in young animals does not serve to reduce tumor burden, 
presumably because klotho levels in young animals already surpass the threshold. In 
addition, increasing klotho too much may increase proliferation of the tumor, as klotho is 
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known to increase cellular proliferation (29).  If this is the case, as suggested by the 
accelerated tumor growth in the rosiglitazone-treated young mice, the age-specific 
nature of this therapy might serve to explain some of the observed discrepancies in 
studies analyzing the role of PPARγ agonists in the therapy of breast and colon cancer.  
Age may play an important role in determining which patients should receive 
rosiglitazone as therapy for melanoma, and since klotho is secreted in the serum, it 
should be relatively simple to determine which patients might benefit from rosiglitazone 
therapy, and which would not. Understanding the role that the aged microenvironment 
plays in modulating cell fates like metastasis and therapy resistance is critical for guiding 
therapy in older patients. 
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Figure Legends 
 
Figure 1. Loss of klotho in the aged microenvironment affects klotho and Wnt5A 
expression in melanoma cells. A, Immunohistochemical analysis of klotho in young 
and aged human skin (60X objective, 1X digital zoom). B, qRT-PCR of klotho mRNA in 
young (N=6) and aged (N=4) human fibroblasts (two-tailed unpaired t-test, p=0.04). C, 
Western analysis of klotho in the media of young and aged human fibroblasts. D, 
Immunofluorescent analysis of klotho (green), HMB45 (red) and Dapi (blue) expression 
in 3D organotypic skin reconstructs built with young or aged fibroblasts (63X objective). 
E, Western analysis of Wnt5A in melanoma cells exposed to DMEM +/- serum, media 
from young fibroblasts or from aged fibroblasts. HSP90 was used as loading control. F, 
Immunofluorescent analysis of Wnt5A (green), HMB45 (red) and Dapi (blue) expression 
in 3D organotypic skin reconstructs built with young or aged fibroblasts (63X objective). 
G, Western analysis of Wnt5A in melanoma cells exposed to media from young 
fibroblasts or young fibroblasts after klotho knock-down or aged fibroblasts +/- 
recombinant klotho. HSP90 was used as loading control. H, Immunofluorescent analysis 
of klotho (green) expression in 3D organotypic skin reconstructs built with young 
fibroblasts infected with either a control shRNA lentivirus or a sh_klotho lentivirus (63X 
objective). HMB45 (red) was used as melanoma cell marker and Dapi (blue) was used to 
stain nuclei. I, Immunofluorescent analysis of Wnt5A (green) expression in 3D 
organotypic skin reconstructs built with young fibroblasts infected with either a control 
shRNA lentivirus or a sh_klotho lentivirus (63X objective). 
 
Figure 2. Wnt5A affects klotho expression via CAMKII mediated inhibition of 
PPARγ. A, Schematic of Wnt5A signaling showing activation of CAMKII, inhibition of 
PPARγ,  and decrease of klotho transcription. Klotho is a sialidase and cleaves Wnt5A 
from syndecans at the cell surface, as we have previously published. B, Western 
analysis of active (phospho) and total CAMKII in melanoma cells treated with indicated 
dose of recombinant Wnt5A for 16h. C, Immunofluorescent analysis of PPARγ and 
klotho in melanoma cells treated with rWnt5A (63X objective). D,qRT-PCR analysis of 
klotho expression in aged fibroblasts treated with the CAMKII inhibitor KN93 (10μM, 48h) 
(two-tailed unpaired t-test, ***=p<0.001). E, Immunofluorescent analysis of PPARγ in 
KN93-treated aged fibroblasts (63X objective). F, Immunofluorescent analysis of PPARγ 
expression in melanoma cells after KN93 treatment (10μM, 48h) (63X objective). G, 
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Immunofluorescent analysis of Klotho expression in melanoma cells after KN93 
treatment (10μM, 48h) (63X objective). H, Immunofluorescent analysis of PPARγ 
expression in aged fibroblasts after treatment with PPARγ agonist Rosiglitazone (Roz) 
(63X objective). I, qRT-PCR analysis of klotho expression in aged fibroblasts treated 
with rosiglitazone (10μM, 48h) (two-tailed unpaired t-test, ***=p<0.001). J, Tumor growth 
curves of Yumm1.7 murine melanoma cells in aged C57/BL6 mice, in the presence of 
recombinant klotho (n=3), rosiglitazone (n=5), or vehicle control (n=4). Tumor burden 
was significantly less in mice treated with recombinant mouse klotho or rosiglitazone. 
Repeated measures analysis of variance (Anova) was calculated between samples. 
Holm Sidak correction was done, ***=p=0.0002 (Day-20). K, Analysis of Klotho and 
Wnt5A levels in mouse tumors by immunohistochemistry analysis after treatment with 
rosiglitazone or vehicle control (40X objective). Data represented as +/- SEM. 
 
Figure 3. Rosiglitazone-mediated inhibition of phospho-Erk can inhibit growth of 
BRAF inhibitor resistant tumors. A, PO4-Erk, Erk, and Wnt5A protein expression 
examined by western blot analysis in BRAF sensitive (Yumm1.7, WM983B, WM793) and 
resistant subclones (Yumm1.7_BR, WM983B_BR, WM793_BR). B, Western blot 
analysis for PO4-Erk and Erk protein expression in WM983b_BR cells after treatment 
with rosiglitazone (10μM) for the indicated time period. C, Expression of PO4-Erk, Erk 
and Wnt5A following treatment with rosiglitazone in WM983b_BR cells transfected with 
Ctrl or Klotho siRNA. D, PO4-Erk, Erk, and Wnt5A protein expression examined by 
western blot analysis in WM983B-BR cells in the presence or absence of PLX4720 in 
conditioned media of aged fibroblasts treated with +/- rosiglitazone. E, Operetta® 
analysis of mito-SOX intensity (measurement of mitochondrial ROS) in WM983B_BR 
cells in the presence or absence of PLX4720 in conditioned media of aged fibroblasts 
treated with vehicle i.e. DMSO:PBS (1:10) or rosiglitazone (Anova p<0.0001; two tailed 
unpaired t-test, ***=p<0.001). C=control; P=plx4720; R= rosiglitazone; R+P= 
Rosiglitazone + plx4720. F, Tumor growth of BRAFi resistant Yumm1.7BR cells in aged 
(52 weeks) C57/BL6mice, +/- PLX4720 and +/- rosiglitazone. N=5 mice/group. Repeated 
measures analysis of variance (Anova) was calculated between samples, p<0.0001. 
Holm Sidak correction was performed, ***=p<0.005 (Day-18). G, Tumor growth of BRAFi 
resistant Yumm1.7BR cells in young (8 weeks) C57/BL6mice, +/- PLX4720 and +/- 
rosiglitazone (N=7 mice/group. Repeated measures analysis of variance (Anova) was 
calculated between samples, p<0.0001. Multiple comparision with Holm Sidak correction 
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was done. H, Klotho levels in aged (left two panels) or young (right two panels) mouse 
serum (western blot) or tumors (immunohistochemistry) after treatment with rosiglitazone 
or vehicle control (40X objective).  
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